Loading
Immunodeficiency and Autoimmune Disorders / Virus-based Gene Therapy Research / CRISPR and Genetic Engineering · Journal article
Expert Opinion on Biological Therapy · July 25, 2026
A consensus or society position rather than new primary data.
This is a narrative review tracing the 30-year evolution of autologous gene therapy for inborn errors of immunity, transitioning from early gamma-retroviral approaches through lentiviral vectors to emerging gene-editing technologies (CRISPR/Cas9, base/prime editing). The review identifies recent clinical success in diseases like WAS and CGD but highlights substantial barriers to accessibility, manufacturing, and affordability that limit equitable implementation.
Journal article. Patients with inborn errors of immunity (IEI), including SCID, Wiskott-Aldrich syndrome (WAS), and chronic granulomatous disease (CGD).
Early gamma-retroviral gene addition successfully restored immunity in SCID but carried high risks of insertional mutagenesis and leukemogenesis Safer self-inactivating lentiviral vectors have been adopted as an alternative approach Emerging gene-editing technologies (CRISPR/Cas9, base/prime editing) offer targeted correction with minimized genotoxicity
No sample sizes, follow-up durations, or safety/efficacy metrics provided for cited milestones in WAS and CGD Emerging gene-editing technologies (CRISPR/Cas9, base/prime editing) offer targeted correction with minimized genotoxicity
Clinicians and researchers should recognize gene therapy as an evolving curative alternative to allogeneic HSCT for selected IEIs, but understand that access, manufacturing complexity, and cost remain major obstacles to widespread adoption. Implementation will require novel regulatory frameworks and collaborative funding models.
A narrative review synthesizing 30 years of gene therapy evolution for inborn errors of immunity, tracing technological advances and identifying barriers to clinical translation, rather than presenting new primary evidence.
Clinicians and researchers should recognize gene therapy as an evolving curative alternative to allogeneic HSCT for selected IEIs, but understand that access, manufacturing complexity, and cost remain major obstacles to widespread adoption. Implementation will require novel regulatory frameworks and collaborative funding models.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
INTRODUCTION: Inborn errors of immunity (IEI) are rare genetic defects that disrupt immune function, often resulting in life-threatening infections, malignancies, and immune dysregulation. Allogeneic hematopoietic stem cell transplantation (HSCT), a curative option for some diagnoses, is limited by donor availability and risks of graft-versus-host disease. This review explores the 30-year evolution of autologous gene therapy as a vital alternative to allogeneic hematopoietic stem cell transplantation for IEIs. AREAS COVERED: Literature search using PubMed for gene therapy for IEI in the last 20 years. We trace the transition from early gamma-retroviral gene addition - which successfully restored immunity in severe combined immunodeficiency (SCID) but carried high risks of insertional mutagenesis and leukemogenesis - to the adoption of safer self-inactivating lentiviral vectors. The field is rapidly advancing beyond viral gene addition toward highly precise gene editing technologies, including CRISPR/Cas9, and base/prime editing, which offer targeted correction with minimized genotoxicity. EXPERT OPINION: Recent milestones in diseases like Wiskott-Aldrich syndrome (WAS) and chronic granulomatous disease (CGD) highlight enormous scientific success, yet significant barriers to accessibility, manufacturing, and affordability remain. Overcoming this requires innovative regulatory frameworks and collaborative funding models. Streamlining development and ensuring equitable access are essential next steps to establishing gene therapy as a safe alternative.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.